A PKMζ inhibitor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Myr-ZIP

Item No. 34445

Technical Information
Formal Name
N-(1-oxotetradecyl)-L-seryl-L-isoleucyl-L-tyrosyl-L-arginyl-L-arginylglycyl-L-alanyl-L-arginyl-L-arginyl-L-tryptophyl-L-arginyl-L-lysyl-L-leucine, trifluoroacetate salt
Synonyms
  • Myristoylated-ZIP
  • Myristoylated Zeta-Pseudosubstrate Inhibitory Peptide
  • Myr-Ser-Ile-Tyr-Arg-Arg-Gly-Ala-Arg-Arg-Trp-Arg-Lys-Leu
  • Myr-SIYRRGARRWRKL-OH
  • Ζeta Inhibitory Peptide
Molecular Formula
C90H154N30O17 • XCF3COOH
Formula Weight
Purity
≥95%
A solid
Water: 1 mg/ml
SMILES
CC(C)C[C@@H](C(O)=O)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@H](C)NC(CNC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H]([C@@H](C)CC)NC([C@H](CO)NC(CCCCCCCCCCCCC)=O)=O)=O)CC1=CC=C(C=C1)O)=O)=O)=O)=O)=O)=O)=O)CC2=CNC3=CC=CC=C23)=O)=O)=O.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C90H154N30O17.C2HF3O2/c1-7-9-10-11-12-13-14-15-16-17-18-36-71(123)110-70(52-121)83(134)120-73(54(5)8-2)84(135)118-67(48-56-37-39-58(122)40-38-56)81(132)115-64(33-25-44-104-88(96)97)77(128)112-61(31-23-42-102-86(92)93)75(126)108-51-72(124)109-55(6)74(125)111-63(32-24-43-103-87(94)95)76(127)114-66(35-27-46-106-90(100)101)79(130)117-68(49-57-50-107-60-29-20-19-28-59(57)60)82(133)116-65(34-26-45-105-89(98)99)78(129)113-62(30-21-22-41-91)80(131)119-69(85(136)137)47-53(3)4;3-2(4,5)1(6)7/h19-20,28-29,37-40,50,53-55,61-70,73,107,121-122H,7-18,21-27,30-36,41-49,51-52,91H2,1-6H3,(H,108,126)(H,109,124)(H,110,123)(H,111,125)(H,112,128)(H,113,129)(H,114,127)(H,115,132)(H,116,133)(H,117,130)(H,118,135)(H,119,131)(H,120,134)(H,136,137)(H4,92,93,102)(H4,94,95,103)(H4,96,97,104)(H4,98,99,105)(H4,100,101,106);(H,6,7)/t54-,55-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,73-;/m0./s1
InChi Key
DHGDHWWJKWLEIM-CQUAHXNOSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    Myr-ZIP is a cell-permeable inhibitor of the constitutively active protein kinase C (PKC) isoform PKMζ (Ki = 0.076-2.11 µM).1,2 It also inhibits PKCα when used at a concentration of 10 µM.3 Myr-ZIP (5 µM) prevents PKC translocation to the plasma membrane induced by ionomycin (Item Nos. 10004974 | 11932) in HEK293 cells expressing A-kinase anchor protein 79 (AKAP79). Myr-ZIP inhibits the conditioned place preference response to morphine in rats when administered intracranially into the nucleus accumbens core at doses of 10 and 30 nmol/0.5 µl per side.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1.  .

    2.  .

    3.  .

    4.  .